by Dan Roberts The field of available equipment and technology for individuals affected by low vision is vast and ever-increasing. The number of products has grown exponentially over the past decade, making it difficult to keep up on new developments. This brief article is for those who would like to know what the market offers [Read More]
Category: Latest News
“Bitterness Gene” May Explain Aversion To Vegetables
The first rule of nutrition for maintaining good retina health is, for some people, the most difficult to swallow. Consuming a diet rich in leafy green vegetables for their high antioxidant values is highly recommended by professional nutritionists and eye care specialists, and no one argues about its preventative value. So why is this rule [Read More]
Zimura® for Dry AMD Continues to Show Positive Results in Trials
In January 2017, Ophthotech Corporation (now known as Iveric), announced that the first patient had been dosed in a Phase 2/3 clinical study of Zimura® (avacincaptad pegol sodium) for treatment of advanced dry macular degeneration (aka geographic atrophy). Zimura® inhibits complement factor C5, which is believed to be involved in the development of AMD. On Oct. 28, [Read More]
Positive Results From RGX-314 Gene Therapy
(Updated 9/10/2020) As reported here in 2017, a drug called RGX-314 is being tested as a one-time sub-retinal injection for wet age-related macular degeneration (wAMD). A preliminary study showed that patients with wAMD had long-term vision stabilization and anatomic improvement following a single treatment with the investigational gene therapy. Now, in a subgroup of patients [Read More]
Abicipar for Wet AMD Maintained Vision Gains Through Year 2
Allergan and Molecular Partners has announced two-year data from their clinical studies of Abicipar in patients with wet age-related macular degeneration (AMD). In the second year of the studies, four injections of Abicipar given 12 weeks apart resulted in maintenance of visual gains comparable to monthly ranibizumab. “We are pleased to see a sustained response at two-years [Read More]